https://m2.mtmt.hu/ hun 2026-09-23 04:23 JournalArticle 33564742 VALIDATED true 0 false 2026-09-22T10:14:33.349+0000 2023-01-30T11:03:34.394+0000 2023-01-16T07:28:20.469+0000 true 10071503 Szabó Regina /api/admin/10071503 Admin Szabó Regina (ELTE TTK admin 5) true 2025-07-29T08:43:48.843+0000 2025-07-29T08:43:48.843+0000 2023-01-23T08:56:06.978+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true Admin 10003134 /api/admin/10003134 Wolf György (MTMT Központi admin) Wolf György true 10003134 true 2025-12-18T14:33:13.723+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Gyenes, Andrea true true /api/journal/10022915 REVIEWED BMC OPHTHALMOLOGY 1471-2415 1471-2415 true false 10022915 false 10022915 true 1471-2415 1471-2415 Journal FOREIGN 23 1 14 14 8 2023 Funding 2022467 /api/funding/2022467 (Open access funding provided by Semmelweis University) false true true 2023 true true true false true false GOLD 2026-09-22 true https://doi.org/10.1186/s12886-022-02761-9 8 0 8 6 2 8 8 6 8 8 8 6 6 6 2 0 8 6 8 6 0 0 0 Folyóiratcikk Journal Article 24 8 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 3 3 3 3 2025 0 3 2 3 2 2026 0 2 1 2 1 Q2 false 10018292 false false false 2023-01-15T07:28:57.650+0000 Immunológiai Tanszék (ELTE / TTK / Bio_I); MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz); Szemészeti Klinika (SE / AOK / K); Szemészeti Klinikai Ismeretek Tanszék (SE / ETK2007) 9 29 4 10 0 true 10003134 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 106310858 /api/authorship/106310858 Gyenes, Andrea [Gyenes, Andrea (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 1 0.1 true false false Author 10048316 /api/author/10048316 Gyenes Andrea (Szemészet) Gyenes Andrea true 10048316 true Gyenes Andrea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310859 /api/authorship/106310859 István, Lilla [István, Lilla (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 2 0.1 false false false Author 10070764 /api/author/10070764 István Lilla (Szemészet) István Lilla true true István Lilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310860 /api/authorship/106310860 Benyó, Fruzsina [Benyó, Fruzsina (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 3 0.1 false false false Author 10070766 /api/author/10070766 Benyó Fruzsina (Szemészet) Benyó Fruzsina true true Benyó Fruzsina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310861 /api/authorship/106310861 Papp, András [Papp, András (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 4 0.1 false false false Author 10024636 /api/author/10024636 Papp András (Szemészet) Papp András true 10024636 true Papp András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310862 /api/authorship/106310862 Resch, Miklós [Resch, Miklós (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 5 0.1 false false false Author 10020318 /api/author/10020318 Resch Miklós (Szemészet) Resch Miklós true 10020318 true Resch Miklós true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310863 /api/authorship/106310863 Sándor, Noémi [Sándor, Noémi (immunológia), szerző] Immunológiai Tanszék (ELTE / TTK / Bio_I); MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz) 6 0.1 false false false Author 10018292 /api/author/10018292 Sándor Noémi (immunológia) Sándor Noémi true 10018292 true Sándor Noémi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310864 /api/authorship/106310864 Józsi, Mihály [Józsi, Mihály (Immunológia), szerző] Immunológiai Tanszék (ELTE / TTK / Bio_I); MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz) 7 0.1 false false false Author 10019323 /api/author/10019323 Józsi Mihály (Immunológia) Józsi Mihály true 10019323 true Józsi Mihály true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310865 /api/authorship/106310865 Nagy, Zoltán Z. [Nagy, Zoltán Zsolt (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K) 8 0.1 false false false Author 10009641 /api/author/10009641 Nagy Zoltán Zsolt (Szemészet) Nagy Zoltán Zsolt true 10009641 true Nagy Zoltán Z. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310866 /api/authorship/106310866 Kovács, Illés ✉ [Kovács, Illés (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Szemészeti Klinikai Ismeretek Tanszék (SE / ETK2007) 9 0.1 false false true Author 10025486 /api/author/10025486 Kovács Illés (Szemészet) Kovács Illés true 10025486 true Kovács Illés true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310867 /api/authorship/106310867 Kiss, Szilárd 10 0.1 false true false Kiss Szilárd true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 22846589 /api/publicationidentifier/22846589 DOI: 10.1186/s12886-022-02761-9 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1186/s12886-022-02761-9 https://doi.org/10.1186/s12886-022-02761-9 false true PublicationIdentifier 22963532 /api/publicationidentifier/22963532 WoS: 000911916900005 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000911916900005 https://www.webofscience.com/wos/woscc/full-record/000911916900005 false true PublicationIdentifier 22917145 /api/publicationidentifier/22917145 Scopus: 85146066866 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85146066866 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85146066866 true true PublicationIdentifier 22917154 /api/publicationidentifier/22917154 PubMed: 36627583 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 36627583 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36627583&dopt=Abstract true true Classification 12311 /api/classification/12311 Szemészet true true SjrRating 11397855 /api/sjrrating/11397855 sjr:Q2 (2023) Scopus - Medicine (miscellaneous) BMC OPHTHALMOLOGY 1471-2415 1471-2415 784 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true Q2 DIRECT true true Reference 37391917 /api/reference/37391917 1. Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009 Nov;116(11):2135–40. https://doi.org/10.1016/j.ophtha.2009.04.017., DOI: 10.1016/j.ophtha.2009.04.017 1 10.1016/j.ophtha.2009.04.017 false true Reference 37391918 /api/reference/37391918 2. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the beaver dam eye study. Ophthalmology. 2002;109:1767–79. https://doi.org/10.1016/s0161-6420(02)01146-6., DOI: 10.1016/s0161-6420(02)01146-6 2 10.1016/s0161-6420(02)01146-6 false true Reference 37391919 /api/reference/37391919 3. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. https://doi.org/10.1016/S2214-109X(13)70145-1., DOI: 10.1016/S2214-109X(13)70145-1 3 10.1016/S2214-109X(13)70145-1 false true Reference 37391920 /api/reference/37391920 4. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol. 2003;87(1):8–12. https://doi.org/10.1136/bjo.87.1.8., DOI: 10.1136/bjo.87.1.8 4 10.1136/bjo.87.1.8 false true Reference 37391921 /api/reference/37391921 5. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains eye study. J Am Geriatr Soc. 1998;46(1):58–64. https://doi.org/10.1111/j.1532-5415.1998.tb01014.x., DOI: 10.1111/j.1532-5415.1998.tb01014.x 5 10.1111/j.1532-5415.1998.tb01014.x false true Reference 37391922 /api/reference/37391922 6. Klein BE, Klein R, Lee KE, Cruickshanks KJ. Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study Ophthalmology. 1998;105(1):160–4. https://doi.org/10.1016/s0161-6420(98)91911-x., DOI: 10.1016/s0161-6420(98)91911-x 6 10.1016/s0161-6420(98)91911-x false true Reference 37391923 /api/reference/37391923 7. West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 1997;38(1):72–82. 7 false true Reference 37391924 /api/reference/37391924 8. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains eye study. J Am Geriatr Soc. 1998;46(1):58–64. https://doi.org/10.1111/j.1532-5415.1998.tb01014.x., DOI: 10.1111/j.1532-5415.1998.tb01014.x 8 10.1111/j.1532-5415.1998.tb01014.x false true Reference 37391925 /api/reference/37391925 9. West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 1997;38(1):72–82. 9 false true Reference 37391926 /api/reference/37391926 10. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120(8):1041–4. https://doi.org/10.1001/archopht.120.8.1041., DOI: 10.1001/archopht.120.8.1041 10 10.1001/archopht.120.8.1041 false true Reference 37391927 /api/reference/37391927 11. Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. Br J Ophthalmol. 2006;90(5):593–6. https://doi.org/10.1136/bjo.2005.086595., DOI: 10.1136/bjo.2005.086595 11 10.1136/bjo.2005.086595 false true Reference 37391928 /api/reference/37391928 12. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci. 1994;35(12):3974–9. 12 false true Reference 37391929 /api/reference/37391929 13. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48. https://doi.org/10.1016/j.ophtha.2012.09.006., DOI: 10.1016/j.ophtha.2012.09.006 13 10.1016/j.ophtha.2012.09.006 false true Reference 37391930 /api/reference/37391930 14. Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, et al. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99(1):92–7. https://doi.org/10.1136/bjophthalmol-2014-305076., DOI: 10.1136/bjophthalmol-2014-305076 14 10.1136/bjophthalmol-2014-305076 false true Reference 37391931 /api/reference/37391931 15. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–6. https://doi.org/10.1136/bjophthalmol-2014-305327., DOI: 10.1136/bjophthalmol-2014-305327 15 10.1136/bjophthalmol-2014-305327 false true Reference 37391932 /api/reference/37391932 16. Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721–31. https://doi.org/10.1038/eye.2015.48., DOI: 10.1038/eye.2015.48 16 10.1038/eye.2015.48 false true Reference 37391933 /api/reference/37391933 17. Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013;97:1443–6. https://doi.org/10.1136/bjophthalmol-2013-303513., DOI: 10.1136/bjophthalmol-2013-303513 17 10.1136/bjophthalmol-2013-303513 false true Reference 37391934 /api/reference/37391934 18. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;2(10):1857–67. https://doi.org/10.2147/DDDT.S97653., DOI: 10.2147/DDDT.S97653 18 10.2147/DDDT.S97653 false true Reference 37391935 /api/reference/37391935 19. Zuber-Laskawiec K, Kubicka-Trzaska A, Karska-Basta I, Pociej-Marciak W, Romanowska-Dixon B. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration. J Physiol Pharmacol. 2019;70(5). https://doi.org/10.26402/jpp.2019.5.13., DOI: 10.26402/jpp.2019.5.13 19 10.26402/jpp.2019.5.13 false true Reference 37391936 /api/reference/37391936 20. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723–31. https://doi.org/10.1097/IAE.0b013e3181a2c1c3., DOI: 10.1097/IAE.0b013e3181a2c1c3 20 10.1097/IAE.0b013e3181a2c1c3 false true Reference 37391937 /api/reference/37391937 21. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21–3. https://doi.org/10.1136/bjo.2011.203893., DOI: 10.1136/bjo.2011.203893 21 10.1136/bjo.2011.203893 false true Reference 37391938 /api/reference/37391938 22. Doguizi S, Ozdek S, Yuksel S. Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration. Int J Ophthalmol. 2015;8(4):846–8. https://doi.org/10.3980/j.issn.2222-3959.2015.04.37., DOI: 10.3980/j.issn.2222-3959.2015.04.37 22 10.3980/j.issn.2222-3959.2015.04.37 false true Reference 37391939 /api/reference/37391939 23. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 23 10.1007/s00417-019-04456-2 false true Reference 37391940 /api/reference/37391940 24. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 24 10.1007/s00417-019-04456-2 false true Reference 37391941 /api/reference/37391941 25. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21–3. https://doi.org/10.1136/bjo.2011.203893., DOI: 10.1136/bjo.2011.203893 25 10.1136/bjo.2011.203893 false true Reference 37391942 /api/reference/37391942 26. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 26 10.1007/s00417-019-04456-2 false true Reference 37391943 /api/reference/37391943 27. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14–20. https://doi.org/10.1136/bjo.2011.204685., DOI: 10.1136/bjo.2011.204685 27 10.1136/bjo.2011.204685 false true Reference 37391944 /api/reference/37391944 28. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol. 2013;97(8):1032–5. https://doi.org/10.1136/bjophthalmol-2013-303344., DOI: 10.1136/bjophthalmol-2013-303344 28 10.1136/bjophthalmol-2013-303344 false true Reference 37391945 /api/reference/37391945 29. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15–22.e1. https://doi.org/10.1016/j.ajo.2013.02.017., DOI: 10.1016/j.ajo.2013.02.017 29 10.1016/j.ajo.2013.02.017 false true Reference 37391946 /api/reference/37391946 30. Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18(4):397–432. https://doi.org/10.1007/s10456-015-9483-4., DOI: 10.1007/s10456-015-9483-4 30 10.1007/s10456-015-9483-4 false true Reference 37391947 /api/reference/37391947 31. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 31 10.1007/s00417-019-04456-2 false true Reference 37391948 /api/reference/37391948 32. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 32 10.1007/s00417-019-04456-2 false true Reference 37391949 /api/reference/37391949 33. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–55. https://doi.org/10.1136/annrheumdis-2012-202220., DOI: 10.1136/annrheumdis-2012-202220 33 10.1136/annrheumdis-2012-202220 false true Reference 37391950 /api/reference/37391950 34. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. https://doi.org/10.1056/NEJMoa054481., DOI: 10.1056/NEJMoa054481 34 10.1056/NEJMoa054481 false true Reference 37391951 /api/reference/37391951 35. Leveziel N, Pelat T, Watier H, Thullier P, Souied EH. Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmologica. 2014;232(1):53–6. https://doi.org/10.1159/000360186., DOI: 10.1159/000360186 35 10.1159/000360186 false true Reference 37391952 /api/reference/37391952 36. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. https://doi.org/10.1056/NEJMoa054481., DOI: 10.1056/NEJMoa054481 36 10.1056/NEJMoa054481 false true Reference 37391953 /api/reference/37391953 37. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3–9. https://doi.org/10.5301/EJO.2010.6049., DOI: 10.5301/EJO.2010.6049 37 10.5301/EJO.2010.6049 false true Reference 37391954 /api/reference/37391954 38. Chen M, Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 2015;98(5):713–25. https://doi.org/10.1189/jlb.3RI0615-239R., DOI: 10.1189/jlb.3RI0615-239R 38 10.1189/jlb.3RI0615-239R false true Reference 37391955 /api/reference/37391955 39. Chen M, Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 2015;98(5):713–25. https://doi.org/10.1189/jlb.3RI0615-239R., DOI: 10.1189/jlb.3RI0615-239R 39 10.1189/jlb.3RI0615-239R false true Reference 37391956 /api/reference/37391956 40. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res. 2009;28(5):348–68. https://doi.org/10.1016/j.preteyeres.2009.06.001., DOI: 10.1016/j.preteyeres.2009.06.001 40 10.1016/j.preteyeres.2009.06.001 false true Reference 37391957 /api/reference/37391957 41. Chen M, Luo C, Zhao J, Devarajan G, Xu H. Immune regulation in the aging retina. Prog Retin Eye Res. 2019;69:159–72. https://doi.org/10.1016/j.preteyeres.2018.10.003., DOI: 10.1016/j.preteyeres.2018.10.003 41 10.1016/j.preteyeres.2018.10.003 false true Reference 37391958 /api/reference/37391958 42. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6., DOI: 10.1016/s1350-9462(98)00022-6 42 10.1016/s1350-9462(98)00022-6 false true Reference 37391959 /api/reference/37391959 43. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3–9. https://doi.org/10.5301/EJO.2010.6049., DOI: 10.5301/EJO.2010.6049 43 10.5301/EJO.2010.6049 false true Reference 37391960 /api/reference/37391960 44. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond). 1995;9(Pt 2):236–40. https://doi.org/10.1038/eye.1995.46., DOI: 10.1038/eye.1995.46 44 10.1038/eye.1995.46 false true Reference 37391961 /api/reference/37391961 45. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6., DOI: 10.1016/s1350-9462(98)00022-6 45 10.1016/s1350-9462(98)00022-6 false true Reference 37391962 /api/reference/37391962 46. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. 1978. Ocul Immunol Inflamm. 2007;15(3):179–85. https://doi.org/10.1080/09273940701382184., DOI: 10.1080/09273940701382184 46 10.1080/09273940701382184 false true Reference 37391963 /api/reference/37391963 47. Streilein JW, Wegmann TG. Immunologic privilege in the eye and the fetus. Immunol Today. 1987;8(12):362–6. https://doi.org/10.1016/0167-5699(87)90209-X., DOI: 10.1016/0167-5699(87)90209-X 47 10.1016/0167-5699(87)90209-X false true Reference 37391964 /api/reference/37391964 48. Sonoda KH, Sakamoto T, Qiao H, Hisatomi T, Oshima T, Tsutsumi-Miyahara C, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology. 2005 Nov;116(3):390–9. https://doi.org/10.1111/j.1365-2567.2005.02239.x., DOI: 10.1111/j.1365-2567.2005.02239.x 48 10.1111/j.1365-2567.2005.02239.x false true Reference 37391965 /api/reference/37391965 49. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond). 1995;9(Pt 2):236–40. https://doi.org/10.1038/eye.1995.46., DOI: 10.1038/eye.1995.46 49 10.1038/eye.1995.46 false true Reference 37391966 /api/reference/37391966 50. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci. 1993;34(12):3347–54. 50 false true Reference 37391967 /api/reference/37391967 51. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6., DOI: 10.1016/s1350-9462(98)00022-6 51 10.1016/s1350-9462(98)00022-6 false true Reference 37391968 /api/reference/37391968 52. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6., DOI: 10.1016/s1350-9462(98)00022-6 52 10.1016/s1350-9462(98)00022-6 false true Reference 37391969 /api/reference/37391969 53. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32(8):2201–11. 53 false true Reference 37391970 /api/reference/37391970 54. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol. 1999;73:72–89. https://doi.org/10.1159/000058738., DOI: 10.1159/000058738 54 10.1159/000058738 false true Reference 37391971 /api/reference/37391971 55. Vinores SA. Breakdown of the Blood–Retinal Barrier. Encyclopedia of the Eye. 2010:216–22. https://doi.org/10.1016/B978-0-12-374203-2.00137-8., DOI: 10.1016/B978-0-12-374203-2.00137-8 55 10.1016/B978-0-12-374203-2.00137-8 false true Reference 37391972 /api/reference/37391972 56. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;21(8):119–26. 56 false true Reference 37391973 /api/reference/37391973 57. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723–31. https://doi.org/10.1097/IAE.0b013e3181a2c1c3., DOI: 10.1097/IAE.0b013e3181a2c1c3 57 10.1097/IAE.0b013e3181a2c1c3 false true Reference 37391974 /api/reference/37391974 58. Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2011;89(2):e206–7. https://doi.org/10.1111/j.1755-3768.2009.01773.x., DOI: 10.1111/j.1755-3768.2009.01773.x 58 10.1111/j.1755-3768.2009.01773.x false true Reference 37391975 /api/reference/37391975 59. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 59 10.1007/s00417-019-04456-2 false true Reference 37391976 /api/reference/37391976 60. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 60 10.1007/s00417-019-04456-2 false true Reference 37391977 /api/reference/37391977 61. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2., DOI: 10.1007/s00417-019-04456-2 61 10.1007/s00417-019-04456-2 false true Reference 37391978 /api/reference/37391978 62. Pikkel J, Attas S. "What should I inject next?" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD. Int Ophthalmol. 2018;38(5):2031–9. https://doi.org/10.1007/s10792-017-0695-z., DOI: 10.1007/s10792-017-0695-z 62 10.1007/s10792-017-0695-z false true Reference 37391979 /api/reference/37391979 63. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;2(10):1857–67. https://doi.org/10.2147/DDDT.S97653., DOI: 10.2147/DDDT.S97653 63 10.2147/DDDT.S97653 false true Reference 37391980 /api/reference/37391980 64. Wu M, Xiong H, Xu Y, Xiong X, Zou H, Zheng M, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Br J Ophthalmol. 2017;101(7):976–84. https://doi.org/10.1136/bjophthalmol-2016-309418., DOI: 10.1136/bjophthalmol-2016-309418 64 10.1136/bjophthalmol-2016-309418 false true Reference 37391981 /api/reference/37391981 65. Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther. 2004;9(3):403–9. https://doi.org/10.1016/j.ymthe.2003.12.005., DOI: 10.1016/j.ymthe.2003.12.005 65 10.1016/j.ymthe.2003.12.005 false true Reference 37391982 /api/reference/37391982 66. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. 2014;10(10):2875–84. https://doi.org/10.4161/hv.29594., DOI: 10.4161/hv.29594 66 10.4161/hv.29594 false true Reference 37391983 /api/reference/37391983 67. Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the eye. Front Immunol. 2013;4:261. https://doi.org/10.3389/fimmu.2013.00261., DOI: 10.3389/fimmu.2013.00261 67 10.3389/fimmu.2013.00261 false true Reference 37391984 /api/reference/37391984 68. Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22(2):116–26. https://doi.org/10.1038/gt.2014.115., DOI: 10.1038/gt.2014.115 68 10.1038/gt.2014.115 false true Reference 37391985 /api/reference/37391985 69. Lee S, Kang IK, Kim JH, Jung BK, Park K, Chang H, et al. Relationship between neutralizing antibodies against adeno-associated virus in the vitreous and serum: effects on retinal gene therapy. Transl Vis Sci Technol. 2019;8(2):14. https://doi.org/10.1167/tvst.8.2.14., DOI: 10.1167/tvst.8.2.14 69 10.1167/tvst.8.2.14 false true Reference 37391986 /api/reference/37391986 70. Kolstad KD, Dalkara D, Guerin K, Visel M, Hoffmann N, Schaffer DV, et al. Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum Gene Ther. 2010;21(5):571–8. https://doi.org/10.1089/hum.2009.194., DOI: 10.1089/hum.2009.194 70 10.1089/hum.2009.194 false true Reference 37391987 /api/reference/37391987 71. Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22(2):116–26. https://doi.org/10.1038/gt.2014.115., DOI: 10.1038/gt.2014.115 71 10.1038/gt.2014.115 false true Reference 37391988 /api/reference/37391988 72. Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–9. 72 false true Reference 37391989 /api/reference/37391989 73. Bartel M, Weinstein J, Schaffer D. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 2012;19:694–700., DOI: 10.1038/gt.2012.20 73 10.1038/gt.2012.20 false true /api/publication/33564742 Gyenes Andrea et al. Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. (2023) BMC OPHTHALMOLOGY 1471-2415 1471-2415 23 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10048316"><a href="/gui2/?type=authors&mode=browse&sel=10048316" target="_blank">Gyenes Andrea (<span class="authorship-author-name">Gyenes Andrea</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10070764"><a href="/gui2/?type=authors&mode=browse&sel=10070764" target="_blank">István Lilla (<span class="authorship-author-name">István Lilla</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10070766"><a href="/gui2/?type=authors&mode=browse&sel=10070766" target="_blank">Benyó Fruzsina (<span class="authorship-author-name">Benyó Fruzsina</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024636"><a href="/gui2/?type=authors&mode=browse&sel=10024636" target="_blank">Papp András (<span class="authorship-author-name">Papp András</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10020318"><a href="/gui2/?type=authors&mode=browse&sel=10020318" target="_blank">Resch Miklós (<span class="authorship-author-name">Resch Miklós</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10018292"><a href="/gui2/?type=authors&mode=browse&sel=10018292" target="_blank">Sándor Noémi (<span class="authorship-author-name">Sándor Noémi</span> <span class="authorAux-mtmt"> immunológia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/Immunológiai Tanszék; <span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/<span title="Immunológiai Tanszék">Imm_Tsz</span>/MTA-ELTE Komplement Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10019323"><a href="/gui2/?type=authors&mode=browse&sel=10019323" target="_blank">Józsi Mihály (<span class="authorship-author-name">Józsi Mihály</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/Immunológiai Tanszék; <span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/<span title="Immunológiai Tanszék">Imm_Tsz</span>/MTA-ELTE Komplement Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10009641"><a href="/gui2/?type=authors&mode=browse&sel=10009641" target="_blank">Nagy Zoltán Z. (<span class="authorship-author-name">Nagy Zoltán Zsolt</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10025486"><a href="/gui2/?type=authors&mode=browse&sel=10025486" target="_blank">Kovács Illés ✉ (<span class="authorship-author-name">Kovács Illés</span> <span class="authorAux-mtmt"> Szemészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Szemészeti Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Egészségtudományi Kar">ETK2007</span>/Szemészeti Klinikai Ismeretek Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kiss Szilárd </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;33564742" target="_blank">Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration</a></div> <div> <span class="journal-title">BMC OPHTHALMOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1471-2415">1471-2415</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1471-2415">1471-2415</a>)</span>: <span class="journal-volume">23</span> <span class="journal-issue">1</span> <span class="page"> Paper 14. 8 p. </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1186/s12886-022-02761-9" target="_blank" href="https://doi.org/10.1186/s12886-022-02761-9"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000911916900005" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000911916900005"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85146066866" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85146066866"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="36627583" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36627583&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Ophthalmology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 8</span> | Független: 6 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 6 | Scopus jelölt:&nbsp;8 | WoS/Scopus jelölt:&nbsp;8 | DOI jelölt:&nbsp;8 </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 33564742</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (Open access funding provided by Semmelweis University) </div> <div class="lastModified">Utolsó módosítás: 2023.01.30. 12:03 Szabó Regina (ELTE TTK admin 5) </div> <div class="lockedBy">Központi kezelésű 2025.12.18. 15:33 Wolf György (MTMT Központi admin) </div> </div></div>